Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J.,…
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Media Release SYDNEY,…
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Media Release SYDNEY,…
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation…
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation…